Class Action Lawsuit Overview
NEW YORK — Pomerantz LLP has announced that a class action lawsuit has been initiated against Altimmune, Inc. This lawsuit allows investors who have sustained losses related to their investment in Altimmune to take action regarding potential securities fraud or other unlawful business practices by the company.
Important Deadlines for Investors
If you have purchased or otherwise acquired Altimmune securities, it's essential to note that you have until October 6, 2025, to petition the Court to appoint you as the Lead Plaintiff in the class action. This is a critical opportunity for affected investors to make their voices heard.
Company and Market Response
The litigation revolves around whether Altimmune, along with certain of its officers or directors, has engaged in deceptive practices that violate securities laws. The specifics of this case emerged following disappointing results from clinical trials conducted by the company.
A Closer Look at the Recent Clinical Trials
On June 26, the company released the topline results from the IMPACT Phase 2b trial of Pemvidutide, aimed at treating MASH (Metabolic Associated Steatotic Liver Disease). Unfortunately, the results indicated that the Company not only failed to achieve the desired statistical significance regarding the fibrosis reduction they had anticipated but also showcased a higher-than-expected placebo response, leading to questions about the company's previous optimistic claims.
Stock Market Impact
Following this news, the stock price of Altimmune dropped significantly, falling $4.10 or approximately 53.2%, to close at $3.61 per share. This sharp decline reflects the market's concern regarding the company's future prospects and the validity of its previous assurances to investors.
Pomerantz LLP's Role in Securities Litigation
Pomerantz LLP stands out as a leader in corporate and securities class action litigation, with deep expertise in holding companies accountable for fraudulent practices. With over 85 years of experience, the firm is committed to championing the rights of investors. Their history of securing substantial damage awards for those misled is well-established, providing hope for investors seeking recovery.
How to Get Involved
If you believe you may be eligible to participate in the class action, please reach out to Danielle Peyton at Pomerantz LLP to discuss your case. It’s crucial to include your mailing address and phone number when making inquiries to ensure timely communication.
Contact Information
Contact:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
Frequently Asked Questions
What is the subject of the class action lawsuit against Altimmune?
The lawsuit centers around allegations of securities fraud and potential violations of business practices by Altimmune, Inc.
How can I join the class action lawsuit?
Investors can join the lawsuit by contacting Pomerantz LLP before the deadline on October 6, 2025.
What happened to Altimmune's stock price?
After disappointing trial results were published, Altimmune's stock fell dramatically by 53.2% in a single day.
Who can be a Lead Plaintiff?
Any investor who purchased or otherwise acquired Altimmune securities during the Class Period may petition the Court to be named as Lead Plaintiff.
What is the significance of this class action?
This class action gives investors a voice in addressing potential misrepresentation and seeking compensation for their losses.
